Biogen Finalizes Apellis Takeover
Biogen closes its takeover of Apellis, gaining SYFOVRE and EMPAVELI while expanding its rare disease and kidney disease portfolio
Clinical Scorecard: Biogen Finalizes Apellis Takeover
At a Glance
Category Detail
Condition Acquisition of Apellis Pharmaceuticals Key Mechanisms Expansion into nephrology and rare disease markets Target Population Patients with geographic atrophy secondary to age-related macular degeneration and kidney transplant patients Care Setting Biotechnology and pharmaceutical industry
Key Highlights
Biogen acquires Apellis Pharmaceuticals, adding two commercial drugs Apellis is now a wholly owned subsidiary of Biogen Transaction valued at $41 per share plus contingent value rights Acquisition expected to enhance earnings growth through the end of the decade Biogen aims to diversify beyond neuroscience Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with geographic atrophy secondary to AMD and those undergoing kidney transplants
SYFOVRE and EMPAVELI generated $689 million in net product revenue during 2025
Clinical Best Practices
Leverage established nephrology infrastructure for future therapies Monitor sales milestones for SYFOVRE to assess contingent value rights Related Resources & Content
